Summary
The capability of tumour cells to escape from therapy-induced senescence, as well as cell-non-autonomous functions of senescence, support the premise that senescence could serve as one pathway to tumour dormancy (among others that include quiescence and diapause) that is permissive for disease recurrence. Consequently, the pharmacologic targeting of senescent tumour cells could mitigate the risk for cancer resurgence, thereby enhancing the therapeutic efficacy of cancer chemotherapy.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The senescence journey in cancer immunoediting
Molecular Cancer Open Access 01 April 2024
-
Dormant cancer cells: programmed quiescence, senescence, or both?
Cancer and Metastasis Reviews Open Access 04 January 2023
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Saleh T, Bloukh S, Carpenter VJ, Alwohoush E, Bakeer J, Darwish S, et al. Therapy-induced senescence: an “old” friend becomes the enemy. Cancers. 2020;12:822.
Wang B, Demaria M. The quest to define and target cellular senescence in cancer. Cancer Res. 2021;81:6087–9.
Zampetidis CP, Galanos P, Papantonis A, Zhu Y, Polyzou A, Karamitros T, et al. A recurrent chromosomal inversion suffices for driving escape from oncogene-induced senescence via subTAD reorganization. Mol Cell. 2021;81:4907–23.
Dirac AMG, Bernards R. Reversal of senescence in mouse fibroblasts through lentiviral suppression of p53. J Biol Chem. 2003;278:11731–4.
Duy C, Li M, Teater M, Meydan C, Garrett-Bakelman FE, Lee TC, et al. Chemotherapy induces senescence-like resilient cells capable of initiating AML recurrence. Cancer Discov. 2021;11:candisc.1375.2020.
Risson E, Nobre AR, Maguer-Satta V, Aguirre-Ghiso JA. The current paradigm and challenges ahead for the dormancy of disseminated tumor cells. Nat Cancer. 2020;1:672–80.
Santos-de-Frutos K, Djouder N. When dormancy fuels tumour relapse. Commun Biol. 2021;4:1–12.
Muñoz DP, Yannone SM, Daemen A, Sun Y, Vakar-Lopez F, Kawahara M, et al. Targetable mechanisms driving immunoevasion of persistent senescent cells link chemotherapy-resistant cancer to aging. JCI Insight. 2019;4:e124716.
Milanovic M, Fan DNY, Belenki D, Däbritz JH, Zhao Z, Yu Y, et al. Senescence-associated reprogramming promotes cancer stemness. Nature. 2018;553:96–100.
Li Y, Kračun D, Dustin CM, El Massry M, Yuan S, Goossen CJ, et al. Forestalling age-impaired angiogenesis and blood flow by targeting NOX: interplay of NOX1, IL-6, and SASP in propagating cell senescence. Proc Natl Acad Sci USA. 2021;118:e2015666118.
Aguirre-Ghiso JA. Translating the science of cancer dormancy to the clinic. Cancer Res. 2021;81:4673–5.
Saleh T, Carpenter V, Tyutyunyk‐Massey L, Murray G, Leverson JD, Souers AJ, et al. Clearance of therapy‐induced senescent tumor cells by the senolytic ABT‐263 via interference with BCL‐X L ‐BAX Interaction. Mol Oncol. 2020;14:1–16.
Carpenter VJ, Saleh T, Gewirtz DA. Senolytics for cancer therapy: is all that glitters really gold? Cancers. 2021;13:723.
Acknowledgements
Research support relating to chemotherapy-induced senescence and senolytics in the Gewirtz laboratory is provided by the NIH/NCI through Grants CA 260819 and CA 239706.
Funding
None.
Author information
Authors and Affiliations
Contributions
TS and DAG contributed to the conceptualisation and writing of the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Ethics approval and consent to participate
Not applicable.
Consent to publish
Not applicable.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Saleh, T., Gewirtz, D.A. Considering therapy-induced senescence as a mechanism of tumour dormancy contributing to disease recurrence. Br J Cancer 126, 1363–1365 (2022). https://doi.org/10.1038/s41416-022-01787-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41416-022-01787-6
This article is cited by
-
The senescence journey in cancer immunoediting
Molecular Cancer (2024)
-
Targeting therapy-induced senescence as a novel strategy to combat chemotherapy-induced peripheral neuropathy
Supportive Care in Cancer (2024)
-
Insights into the role of senescence in tumor dormancy: mechanisms and applications
Cancer and Metastasis Reviews (2023)
-
A three-marker signature identifies senescence in human breast cancer exposed to neoadjuvant chemotherapy
Cancer Chemotherapy and Pharmacology (2023)
-
Cellular senescence in glioma
Journal of Neuro-Oncology (2023)